The hospital achieved this recognition by meeting rigorous standards for performing endovascular thrombectomy and demonstrating continuous compliance with its performance standards.
The Phillips School of Nursing at Mount Sinai Beth Israel (PSON) has been awarded more than $1.8 million over four years from the Health Resources & Services Administration (HRSA) to build on the school’s efforts in recruiting a diverse group of students and further creating an equitable environment. The grant is made possible through the Nursing Workforce Diversity Program, which helps to recruit, support, retain, and graduate nursing students from disadvantaged backgrounds including racial and ethnic minorities underrepresented in nursing.
Patients with a type of blood cancer called multiple myeloma had a widely variable response to COVID-19 vaccines—in some cases, no detectable response—pointing to the need for antibody testing and precautions for these patients after vaccination, according to a study published in Cancer Cell in June.
An oral medication called upadacitinib yielded rapid and significant improvements in patients with moderate to severe atopic dermatitis (AD), also known as eczema, in phase 3 clinical trials, Mount Sinai researchers reported today in The Lancet online.
A combination of remdesivir, a drug currently approved in the United States for treating COVID-19 patients, and repurposed drugs for hepatitis C virus (HCV) was 10 times more effective at inhibiting SARS-CoV-2, the virus that causes COVID-19.
With highly trained specialists skilled in caring for different types of melanoma, patients at the Waldman Melanoma and Skin Center will have access to the newest diagnostics and therapies such as Canfield Vectra180 – a 3D whole body imaging system that captures nearly the entire skin surface in macro quality resolution, and will be able to capture early skin cancer lesions; Nevisense—a safe diagnostic support tool utilizing Electrical Impedence Spectroscopy (EIS) which is applied as a harmless electrical signal to the skin; Vivascope 1500—a non-invasive confocal imaging system which offers a non-invasive way to image the skin to the superficial collagen layers; and innovative technologies which non-invasively collects skin cells through adhesive patches rather than a scalpel to diagnose atypical pigmented lesions (or moles) at high risk for melanoma.
The Mount Sinai Hospital is the first academic center in the Northeast region to teach Aquablation® therapy—a robotically guided advanced new therapy and minimally invasive procedure used to treat enlarged prostates, a common condition technically known as benign prostatic hyperplasia (BPH). The teaching program is being led by Steven A. Kaplan, MD, Professor of Urology, Icahn School of Medicine at Mount Sinai and Director of the Men’s Wellness Program, Mount Sinai Health System.
Molecules called microRNAs (miRNAs) that are measurable in urine have been identified by researchers at Mount Sinai as predictors of both heart and kidney health in children without disease. The epidemiological study of Mexican children was published in February in the journal Epigenomics.
This is the first study to demonstrate that there is no difference in blood clots when transgender women remain on estrogen hormone therapy for gender affirming surgery. Because both estrogen therapy and surgery can increase a person’s risk of blood clots, experts had long suggested that transgender women stop taking estrogen when undergoing gender affirming surgery. However, there was previously no published data on the blood clot risk specific to transgender women undergoing surgery.
The Tisch Cancer Institute at Mount Sinai has been awarded a $1.9 million grant by the National Cancer Institute for an innovative study that will explore the mechanisms that enable tumor cells to spread from their original site but remain dormant for some time before becoming metastatic and threatening the lives of patients.
The Dubin Breast Center of The Tisch Cancer Institute at the Mount Sinai Health System celebrated its 10th anniversary during its annual gala on Monday, December 7, 2020. The evening honored Eva Andersson-Dubin, MD, founder of the Center and a Mount Sinai trustee, and Elisa Port, MD, FACS, the Center’s Director and Chief of Breast Surgery for the Mount Sinai Health System, and raised more than $2.3 million to benefit the Dubin Breast Center. The center is part of The Tisch Cancer Institute, a National Cancer Institute-designated cancer center.
Growing numbers of COVID-19 cases and deaths are troubling; facemasks can slow the trend
Mount Sinai has received a $4 million donation from Lizzie and Jonathan Tisch to support prostate health and the Milton and Carroll Petrie Department of Urology at Mount Sinai.
Mount Sinai Doctors has opened a new location in Scarsdale, New York, that includes a team of highly skilled physicians and nurses, and services that include primary care, cardiology, gastroenterology, orthopedics, gynecology, and many others. The new, state-of-the-art facility is 15,000 square feet and located at 341 Central Park Avenue, Scarsdale, NY.
Seven hospitals within the Mount Sinai Health System have been recognized as national leaders in LGBTQ health care equality by the Human Rights Campaign Foundation’s 2020 Healthcare Equality Index (HEI).
A research team from Mount Sinai has unraveled for the first time the three-dimensional structure and mechanism of a complex enzyme that protects cells from constant DNA damage, opening the door to discovery of new therapeutics for the treatment of chemotherapy-resistant cancers.
Research from the Mount Sinai Health System, just posted to pre-print server MedRxiv (https://www.medrxiv.org/content/10.1101/2020.07.14.20151126v1), shows that the vast majority (more than 90%) of infected individuals with mild-to-moderate COVID 19 experience robust IgG antibody responses against the viral spike protein. The researchers also show…
Researchers at the Icahn School of Medicine report that roflumilast cream (ARQ-151), which contains a highly potent, selective phosphodiesterase-4 (PDE4) inhibitor demonstrated significant improvements in patients with psoriasis signs and symptoms in as early as two weeks. The phase 2b trial results showed that when patients with plaque psoriasis applied topical roflumilast once-daily they reported clear skin as well as improvement in itch and burden of disease. The results of the paper were published online today in The New England Journal of Medicine.
Mount Sinai Health System and Cross County Cardiology announced a new cooperative partnership today that will include five cardiology practices located throughout Bergen and Hudson counties in New Jersey. Cross County Cardiology-Mount Sinai Doctors will work to enhance clinical care for patients with cardiovascular disease bringing the most advanced techniques within the field of cardiology and vascular care to the region.
A health care system (The Mount Sinai Hospital) and a Medicaid payer (Healthfirst) partnered to develop an educational intervention and payment redesign program to improve timely postpartum visits for low-income high-risk mothers in New York City between April 2015 and October 2016.
The study will aim to understand whether systemic medications and biologics, such as dupilumab—a monoclonal antibody that binds to an inflammatory molecule, IL-4 receptor alfa, and inhibits the inflammatory response that leads to rashes and itching from atopic dermatitis/eczema—may have a positive or negative impact on COVID-19 responses in patients who have the disease.
Mount Sinai and Emergent to conduct clinical trials to evaluate COVID-HIG for post-exposure prophylaxis of COVID-19 in front-line health care workers and to support a potential Expanded Access Program for military personnel with funding from the U.S. Department of Defense
– ImmunoTek to extend operating license and provide training to Mount Sinai to establish onsite plasma collection to support production of COVID-HIG
An interprofessional simulation-based educational program helped Mount Sinai Hospital train nearly 90% of its medical ICU staff to care for patients in prone position, as part of its 2018 implementation of a new protocol related to prone position ventilation for patients with acute respiratory distress syndrome.
Responders who worked at the World Trade Center site after the attacks on September 11, 2001, have an increased overall cancer incidence compared to the general population, particularly in thyroid cancer, prostate cancer, and, for the first time ever reported, leukemia, according to a Mount Sinai study published in JNCI Cancer Spectrum in January.
A mother’s exposure to particulate air pollution during pregnancy is associated with reduced cardiac response to stress in six-month-old infants, according to Mount Sinai research published in Environmental Health Perspectives in October. This study is the first to find that particulate air pollution exposure in utero can affect heart rate variability, which is a known risk factor for health issues.
Three world-renowned environmental health researchers from the Institute for Exposomic Research at Mount Sinai have been awarded grants worth a total of $25 million from the National Institutes of Health (NIH) for the newly formed Human Health Environmental Assessment Resource (HHEAR). This program is dedicated to measuring all the environmental factors faced in people’s lives—a new science called “exposomics,” which is expected to yield important insights about disease processes and potential treatments.
Mount Sinai researchers have identified a targeted therapy for adolescent patients with neuroblastoma, a deadly pediatric nerve cancer, who would otherwise have no treatment options, according to a study published in October in Cancer Cell.